PCVX - Vaxcyte, Inc.
58.25
-1.880 -3.227%
Share volume: 1,324,745
Last Updated: 03-05-2026
Pharmaceutical Products/Biological Products, Except Diagnostic Substances:
-0.04%
PREVIOUS CLOSE
CHG
CHG%
$60.13
-1.88
-0.03%
View ratios
| Fiscal Date | 03-31-2024 | 06-30-2024 | 09-30-2024 | 12-31-2024 | 03-31-2025 | 09-30-2025 | 12-31-2025 | |
|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q3 2025 | Q4 2025 | |
| Report Date | 05-08-2024 | 08-06-2024 | 11-05-2024 | 02-25-2025 | 05-07-2025 | 11-04-2025 | 02-24-2026 | |
| Total revenue | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Cost of revenue | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Gross profit | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| nan% | nan% | nan% | nan% | nan% | ||||
| Operating expenses | 114.472 M | 152.981 M | 139.924 M | 162.169 M | 180.793 M | 242.380 M | 274.283 M | |
| Selling general and admin | 19.885 M | 21.474 M | 22.988 M | 28.555 M | 32.659 M | 32.447 M | 32.223 M | |
| Research and development | 94.587 M | 131.507 M | 116.936 M | 133.614 M | 148.134 M | 209.933 M | 242.060 M | |
| Total expenses | 114.472 M | 152.981 M | 139.924 M | 162.169 M | 180.793 M | 242.380 M | 274.283 M | |
| 33.64% | -8.54% | 15.90% | 11.48% | 34.06% | 13.16% | |||
| Operating income | -114.472 M | -152.981 M | -139.924 M | -162.169 M | -180.793 M | -242.380 M | -274.283 M | |
| Ebit | -116.812 M | -152.543 M | -131.181 M | -173.385 M | -173.653 M | -242.089 M | -272.958 M | |
| Pretax income | -95.020 M | -128.730 M | -103.124 M | -137.053 M | -140.718 M | -212.830 M | -246.507 M | |
| 35.48% | -19.89% | 32.90% | 2.67% | 51.25% | 15.82% | |||
| Income tax | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income basic | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income | -95.020 M | -128.703 M | -103.124 M | -137.080 M | -140.718 M | -212.830 M | -246.507 M | |
| -35.45% | 19.87% | -32.93% | -2.65% | -51.25% | -15.82% |